🔗 Share this article

This year's Nobel Prize in Physiology or Medicine has been granted for transformative discoveries that clarify how the immune system targets harmful infections while protecting the healthy tissues.

A trio of renowned researchers—Japan's Shimon Sakaguchi and US experts Dr. Brunkow and Dr. Ramsdell—share this honor.

The research identified specialized "sentinels" within the immune system that remove rogue defense cells capable of harming the organism.

These findings are now paving the way for new therapies for immune disorders and cancer.

The laureates will divide a prize fund valued at 11 million Swedish kronor.

Crucial Findings

"Their work has been essential for understanding how the immune system functions and why we don't all suffer from severe autoimmune diseases," stated the head of the award panel.

This team's studies explain a core mystery: How does the immune system defend us from countless invaders while leaving our healthy cells intact?

The immune system employs white blood cells that search for signs of disease, even viruses and bacteria it has never encountered.

Such cells utilize detectors—called recognition units—that are produced by chance in countless combinations.

This gives the immune system the ability to fight a broad range of invaders, but the unpredictability of the process unavoidably creates immune cells that can attack the host.

Security Guards of the Body

Scientists earlier understood that a portion of these harmful white blood cells were destroyed in the thymus—the site where white blood cells develop.

The latest award honors the identification of regulatory T-cells—described as the immune system's "peacekeepers"—which travel through the body to disarm any immune cells that attack the healthy cells.

We know that this process fails in self-attack conditions such as type-1 diabetes, MS, and RA.

The prize committee added, "The findings have established a novel area of research and accelerated the development of innovative treatments, for example for tumors and autoimmune diseases."

In malignancies, T-regs block the system from attacking the growth, so studies are focused on lowering their quantity.

For autoimmune diseases, trials are testing boosting T-reg cells so the body is not under attack. A similar approach could also be useful in reducing the risks of transplanted organ failure.

Innovative Studies

Prof Shimon Sakaguchi, of Osaka University, performed experiments on rodents that had their immune gland removed, leading to self-attack conditions.

The researcher demonstrated that injecting immune cells from other mice could stop the illness—suggesting there was a system for preventing immune cells from attacking the host.

Mary Brunkow, affiliated with the a research center in a US city, and Dr. Ramsdell, currently at a biotech firm in a California city, were investigating an inherited immune disorder in mice and humans that resulted in the identification of a gene critical for the way T-regs function.

"The pioneering work has uncovered how the immune system is kept in check by regulatory T cells, stopping it from mistakenly targeting the healthy cells," commented a prominent physiology specialist.

"The work is a remarkable illustration of how basic physiological research can have broad consequences for human health."